Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04315181 · ClinicalTrials.gov registry record · Phase 1
Prescription Medication Interactions
A Phase 1 study, sponsored by Sharon Walsh.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04315181 is a Phase 1 study that has completed, run by Sharon Walsh. The registered enrollment target is 11 participants.
The verdict
NCT04315181, a Phase 1 study, has completed, sponsored by Sharon Walsh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.
Interventions
- DRUG Opioid Agonist
- DRUG Sedatives
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04315181
The ClinicalTrials.gov registry entry for NCT04315181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sharon Walsh, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Opioid Agonist is the first listed.
NCT04315181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04315181 about?
NCT04315181 is a clinical study titled "Prescription Medication Interactions". This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interactio...
What is the current status of trial NCT04315181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2019-03-25. Estimated completion is 2023-05-06.
What interventions are being tested in trial NCT04315181?
The interventions under investigation include: Opioid Agonist (DRUG), Sedatives (DRUG).
Who is sponsoring clinical trial NCT04315181?
This trial is sponsored by Sharon Walsh, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.